• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

肺癌骨转移所致病理性骨折：危险因素与生存情况

PATHOLOGICAL FRACTURES DUE TO BONE METASTASES FROM LUNG CANCER: RISK FACTORS AND SURVIVAL.

作者信息

Oliveira Marcelo Bragança Dos Reis, Marques Bruno de Carvalho, Matos Rosa Aurílio, Fontenelle César Rubens da Costa, Mello Fernanda Carvalho de Queiroz, Paschoal Marcos Eduardo Machado

机构信息

Universidade Federai do Rio de Janeiro, Rio de Janeiro, RJ, Brazil.

Escola de Saúde do Exército, Rio de Janeiro, RJ, Brazil.

出版信息

Acta Ortop Bras. 2018;26(6):388-393. doi: 10.1590/1413-785220182606201669.

DOI:10.1590/1413-785220182606201669
PMID:30774512
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC6362688/
Abstract

INTRODUCTION

Pathological fractures are frequent skeletal-related events among lung cancer patients, which result in high morbidity and decreased overall survival and make operative treatment decisions challenging.

OBJECTIVES

To identify risk factors associated with the occurrence of pathological fractures in patients with lung cancer and to determine survival.

METHODS

We conducted a retrospective cohort study with 407 lung carcinoma patients diagnosed between 2006 and 2015. The prevalence of bone metastases and pathological fractures was calculated. Statistical analysis was conducted using a chi-squared test, and the odds ratio and 95% confidence interval were calculated. Overall survival was determined using the Kaplan-Meier method and differences were compared using the log-rank test.

RESULTS

The prevalence of bone metastases and pathological fractures was 28.2% (n = 115) and 19.1% (n = 22), respectively. Pathological fractures were more frequent among patients with bone metastases at the time of diagnosis of lung cancer (24.7% [n = 20] vs. 5.9% [n = 2]; p < 0.05). The median overall survival following the diagnosis of lung cancer, bone metastases, and pathological fracture was 6, 4, and 2 months, respectively.

CONCLUSIONS

Pathological fracture was associated with synchronous bone metastases and overall survival times were considerably reduced.

摘要

引言

病理性骨折是肺癌患者常见的骨相关事件，导致高发病率和总生存期缩短，给手术治疗决策带来挑战。

目的

确定肺癌患者病理性骨折发生的相关危险因素并确定生存期。

方法

我们对2006年至2015年间诊断的407例肺癌患者进行了一项回顾性队列研究。计算骨转移和病理性骨折的患病率。采用卡方检验进行统计分析，并计算比值比和95%置信区间。采用Kaplan-Meier方法确定总生存期，并使用对数秩检验比较差异。

结果

骨转移和病理性骨折的患病率分别为28.2%（n = 115）和19.1%（n = 22）。肺癌诊断时伴有骨转移的患者病理性骨折更为常见（24.7% [n = 20] 对5.9% [n = 2]；p < 0.05）。肺癌、骨转移和病理性骨折诊断后的中位总生存期分别为6个月、4个月和2个月。

结论

病理性骨折与同步骨转移相关，总生存时间显著缩短。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9a43/6362688/516520b03e10/1809-4406-aob-26-06-0388-gf04.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9a43/6362688/2633a605a9c3/1809-4406-aob-26-06-0388-gf01.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9a43/6362688/eab175405487/1809-4406-aob-26-06-0388-gf02.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9a43/6362688/6ac213f47d61/1809-4406-aob-26-06-0388-gf03.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9a43/6362688/516520b03e10/1809-4406-aob-26-06-0388-gf04.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9a43/6362688/2633a605a9c3/1809-4406-aob-26-06-0388-gf01.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9a43/6362688/eab175405487/1809-4406-aob-26-06-0388-gf02.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9a43/6362688/6ac213f47d61/1809-4406-aob-26-06-0388-gf03.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9a43/6362688/516520b03e10/1809-4406-aob-26-06-0388-gf04.jpg

相似文献

1
PATHOLOGICAL FRACTURES DUE TO BONE METASTASES FROM LUNG CANCER: RISK FACTORS AND SURVIVAL.肺癌骨转移所致病理性骨折：危险因素与生存情况
Acta Ortop Bras. 2018;26(6):388-393. doi: 10.1590/1413-785220182606201669.
2
The cost of treatment of skeletal-related events in patients with bone metastases from lung cancer.肺癌骨转移患者骨相关事件的治疗费用。
Oncology. 2004;67(5-6):390-6. doi: 10.1159/000082923.
3
The relationship between lung cancer histology and the clinicopathological characteristics of bone metastases.肺癌组织学与骨转移瘤临床病理特征之间的关系
Lung Cancer. 2016 Jun;96:19-24. doi: 10.1016/j.lungcan.2016.03.014. Epub 2016 Mar 26.
4
The Impact of Lung Carcinoma Histology on the Frequency of Bone Metastases.肺癌组织学对骨转移频率的影响。
Rev Bras Ortop (Sao Paulo). 2019 Sep;54(5):524-530. doi: 10.1016/j.rbo.2018.02.002. Epub 2019 Sep 19.
5
Does surgical technique influence the burden of lung metastases in patients with pathologic long bone fractures?手术技术是否会影响病理性长骨骨折患者肺转移的负担？
BMC Musculoskelet Disord. 2022 Jan 31;23(1):102. doi: 10.1186/s12891-022-05067-5.
6
Retrospective evaluation of the clinical benefit of long-term continuous use of zoledronic acid in patients with lung cancer and bone metastases.回顾性评估肺癌伴骨转移患者长期连续使用唑来膦酸的临床获益。
J Med Econ. 2012;15(1):195-204. doi: 10.3111/13696998.2011.650489. Epub 2011 Dec 23.
7
Prevalence and factors associated with the occurrence of pathological fractures and their impact on the overall survival of patients with bone metastases under palliative care.姑息治疗下骨转移患者病理性骨折的发生率、相关因素及其对总生存的影响
BMJ Support Palliat Care. 2023 Oct 31. doi: 10.1136/spcare-2023-004582.
8
Bisphosphonates for breast cancer.用于乳腺癌的双膦酸盐类药物。
Cochrane Database Syst Rev. 2005 Jul 20(3):CD003474. doi: 10.1002/14651858.CD003474.pub2.
9
Epidermal growth factor receptor mutations should be considered as a prognostic factor for survival of patients with pathological fractures or painful bone metastases from non-small cell lung cancer.表皮生长因子受体突变应被视为非小细胞肺癌病理性骨折或疼痛性骨转移患者生存的一个预后因素。
Bone Joint J. 2017 Apr;99-B(4):516-521. doi: 10.1302/0301-620X.99B4.BJJ-2016-0872.R1.
10
Should the Use of Biologic Agents in Patients With Renal and Lung Cancer Affect Our Surgical Management of Femoral Metastases?生物制剂在肾癌和肺癌患者中的应用是否会影响我们对股骨转移瘤的手术治疗？
Clin Orthop Relat Res. 2019 Apr;477(4):707-714. doi: 10.1097/CORR.0000000000000434.

引用本文的文献

1
Increased Number of Medical Comorbidities Associated With Increased Risk of Presenting With Pathological Femur Fracture in Metastatic Bone Disease.患有转移性骨疾病的患者，其合并症数量的增加与病理性股骨骨折的发生风险增加相关。
Iowa Orthop J. 2023;43(1):87-93.
2
Functional Decline as an Indicator of Ill-Health: A Retrospective Case Study of the Process Leading to Lung Cancer.功能衰退作为健康不佳的指标：一项关于肺癌发病过程的回顾性案例研究
J Multidiscip Healthc. 2021 Apr 27;14:919-927. doi: 10.2147/JMDH.S295498. eCollection 2021.
3
Clinical features and prognostic factors in patients with bone metastases from non-small cell lung cancer.

本文引用的文献

1
The relationship between lung cancer histology and the clinicopathological characteristics of bone metastases.肺癌组织学与骨转移瘤临床病理特征之间的关系
Lung Cancer. 2016 Jun;96:19-24. doi: 10.1016/j.lungcan.2016.03.014. Epub 2016 Mar 26.
2
Incidence and consequences of bone metastases in lung cancer patients.肺癌患者骨转移的发生率及后果
J Bone Oncol. 2013 Jan 17;2(1):22-9. doi: 10.1016/j.jbo.2012.12.004. eCollection 2013 Feb.
3
The incidence and clinical impact of bone metastases in non-small cell lung cancer.
非小细胞肺癌骨转移患者的临床特征和预后因素。
J Int Med Res. 2020 May;48(5):300060520925644. doi: 10.1177/0300060520925644.
4
Analgesia of percutaneous thermal ablation plus cementoplasty for cancer bone metastases.经皮热消融联合骨水泥成形术治疗癌性骨转移的镇痛效果
J Bone Oncol. 2019 Nov 5;19:100266. doi: 10.1016/j.jbo.2019.100266. eCollection 2019 Dec.
非小细胞肺癌骨转移的发生率及临床影响
Lung Cancer. 2015 Aug;89(2):197-202. doi: 10.1016/j.lungcan.2015.04.007. Epub 2015 May 11.
4
Bone metastasis, skeletal-related events, and mortality in lung cancer patients: a Danish population-based cohort study.肺癌患者的骨转移、骨相关事件及死亡率：一项基于丹麦人群的队列研究。
Lung Cancer. 2014 Nov;86(2):247-54. doi: 10.1016/j.lungcan.2014.08.022. Epub 2014 Sep 10.
5
Reossification of osteolytic metastases at the acetabulum following gefitinib and multidisciplinary treatment for lung cancer: a case report with autopsy findings.吉非替尼及多学科治疗肺癌后髋臼溶骨性转移灶的再骨化：一例伴有尸检结果的病例报告
J Orthop Sci. 2015 Sep;20(5):914-8. doi: 10.1007/s00776-014-0562-y. Epub 2014 Apr 1.
6
Predicting Survival in Patients with Advanced Non-squamous Non-small Cell Lung Cancer: Validating the Extent of Metastasis.预测晚期非鳞状非小细胞肺癌患者的生存：验证转移程度。
Cancer Res Treat. 2013 Jun;45(2):95-102. doi: 10.4143/crt.2013.45.2.95.
7
Mortality following bone metastasis and skeletal-related events among patients 65 years and above with lung cancer: A population-based analysis of U.S. Medicare beneficiaries, 1999-2006.65岁及以上肺癌患者骨转移和骨相关事件后的死亡率：基于美国医疗保险受益人的人群分析，1999 - 2006年
Lung India. 2013 Jan;30(1):20-6. doi: 10.4103/0970-2113.106127.
8
Survival of patients with non-small cell lung cancer without treatment: a systematic review and meta-analysis.未经治疗的非小细胞肺癌患者的生存：系统评价和荟萃分析。
Syst Rev. 2013 Feb 4;2:10. doi: 10.1186/2046-4053-2-10.
9
Bone matters in lung cancer.肺癌与骨骼有关。
Ann Oncol. 2012 Sep;23(9):2215-2222. doi: 10.1093/annonc/mds009. Epub 2012 Feb 22.
10
Epidemiology and treatment costs of bone metastases from lung cancer: a French prospective, observational, multicenter study (GFPC 0601).肺癌骨转移的流行病学和治疗费用：一项法国前瞻性、观察性、多中心研究（GFPC 0601）。
J Thorac Oncol. 2011 Mar;6(3):576-82. doi: 10.1097/JTO.0b013e318206a1e3.